Bakır Mesut, Rumeli Şebnem, Pire Argun
Pain Management, Mersin City Education and Research Hospital, Mersin, TUR.
Anesthesiology and Reanimation, Mersin University Faculty of Medicine, Mersin, TUR.
Cureus. 2023 Sep 14;15(9):e45223. doi: 10.7759/cureus.45223. eCollection 2023 Sep.
Objectives A multimodal approach to pain management, including potential interventional techniques, is suggested to achieve adequate pain control. This study discusses the techniques and medications employed to manage pain in pediatric oncology patients. Methodology This study included 90 patients under 18 years of age who underwent pain management in the algology clinic between 2002 and 2020. From the algology follow-up records, the following data were recorded: demographic information, follow-up time, cancer diagnosis and stage, cause and location of pain, systems involved, duration and intensity of pain, analgesic and adjuvant drugs prescribed, routes and duration of drug administration, complications, interventional procedures if performed, "pain intensity" scores prior to and following treatment, and daily and total analgesic consumption of the patients. Results The mean age was 11.4±4.1 years (min-max: 2-17). Leukemia and lymphoma were the most frequently diagnosed (30%). Of the 31 features identified in the staging, 27 (87.1%) were stage 4 at admission. The causes of pain in children were neoplasms in 81.2% ( = 73). At admission, 72.3% ( = 65) had severe pain for at least a month. It was determined that 90% ( = 81) of the patients were using opioids and 28.9% ( = 26) were using dual opioids. The mean tramadol dose was 129.0±97.9 mg/day (12-380 mg/day), and the mean morphine dose was 14.8±11.3 mg/day (1-52 mg/day). The mean transdermal fentanyl dose was 33.2±21.6 µgr/h (12-75 µgr/h). Adjuvant therapy was administered in 25.6% ( = 24) of the patients. Epidural catheterization was performed on 6.6% ( = 6) of the patients. The mean initial pain scores were 5.2±1.7, which decreased to 1.5±0.7 with a significant difference ( < 0.001). In the study, 93% ( = 84) of the patients had no pain management complications noted. Conclusions The pain level that pediatric cancer patients endure critically influences their and their family's quality of life. The fact that opioid-related adverse effects associated with pediatric pain management occur far less frequently than previously thought may help prevent opiophobia. Effective and safe analgesia can be provided with multimodal analgesia to manage pediatric cancer pain.
目的 建议采用多模式疼痛管理方法,包括潜在的介入技术,以实现充分的疼痛控制。本研究讨论了用于管理儿科肿瘤患者疼痛的技术和药物。方法 本研究纳入了90名18岁以下的患者,他们于2002年至2020年期间在疼痛科接受了疼痛管理。从疼痛科的随访记录中,记录了以下数据:人口统计学信息、随访时间、癌症诊断和分期、疼痛的原因和部位、涉及的系统、疼痛的持续时间和强度、开具的镇痛药和辅助药物、给药途径和持续时间、并发症、是否进行介入操作、治疗前后的“疼痛强度”评分以及患者的每日和总镇痛药消耗量。结果 平均年龄为11.4±4.1岁(最小-最大:2-17岁)。白血病和淋巴瘤是最常见的诊断疾病(30%)。在分期确定的31个特征中,27个(87.1%)在入院时为4期。儿童疼痛的原因中,81.2%(n = 73)是肿瘤。入院时,72.3%(n = 65)至少有一个月的重度疼痛。确定90%(n = 81)的患者使用阿片类药物,28.9%(n = 26)使用双重阿片类药物。曲马多的平均剂量为129.0±97.9毫克/天(12-380毫克/天),吗啡的平均剂量为14.8±11.3毫克/天(1-52毫克/天)。透皮芬太尼的平均剂量为33.2±2,1.6微克/小时(12-75微克/小时)。25.6%(n = 24)的患者接受了辅助治疗。6.6%(n = 6)的患者进行了硬膜外导管置入术。初始疼痛评分的平均值为5.2±1.7,降至1.5±0.7,差异有统计学意义(P < 0.001)。在该研究中,93%(n = 84)的患者未发现疼痛管理并发症。结论 儿科癌症患者忍受的疼痛程度严重影响他们及其家人的生活质量。与儿科疼痛管理相关的阿片类药物不良反应发生频率远低于先前认为的情况,这可能有助于预防阿片恐惧症。多模式镇痛可提供有效且安全的镇痛,以管理儿科癌症疼痛。